De novo paternal origin duplication of chromosome 11p15.5: report of two Chinese cases with Beckwith-Wiedemann syndrome

Qin Wang, Qian Geng, Qinghua Zhou, Fuwei Luo, Peining Li and Jiansheng Xie

Abstract

Background: The molecular etiology of Beckwith-Wiedemann syndrome (BWS) is complex and heterogeneous. Several subtypes of epigenetic-genetic alterations including aberrant methylation patterns, segmental uniparental disomy, single gene mutations, and copy number changes have been described. An integrated molecular approach to analyze the epigenetic-genetic alterations is required for accurate diagnosis of BWS.

Case presentation: We reported two Chinese cases with BWS detected by genome-wide copy number analysis and locus-specific methylation profiling. Prenatal analysis on cord blood of patient 1 showed a de novo paternal origin duplication spanning 896Kb at 11p15.5. Patient 2 was referred at 2-month old and the genetic analysis showed a de novo 228.8Kb deletion at 11p15.5 telomeric end and a de novo duplication of 2.5 Mb at 11p15.5–15.4. Both the duplications are of paternal origin with gain of methylation at the imprinting center 1 and thus belong to the subgroup of a low tumor risk.

Conclusion: Results from these two cases and other reported cases from literature indicated that paternally derived duplications at 11p15.5 region cause BWS. Combined chromosome microarray analysis and methylation profiling provided reliable diagnosis for this subtype of BWS. Characterization of genetic defects in BWS patients could lead to better understanding the genetic mechanisms of this clinically and genetically heterogeneous disorder.

Keywords: Beckwith–Wiedemann syndrome (BWS), Chromosome 11p15.5, Imprinting centers (IC), Paternal duplication, Chromosomal microarray analysis (CMA), Methylation-specific multiplex ligation-dependent probe amplification (MS-MLPA)

Background

Human chromosome 11p15.5 contains a one megabase (Mb) cluster of evolutionarily conserved imprinted genes [1]. The expression of these imprinted genes is regulated by two different imprinting centers (IC) 1 and 2. Epigenetic and genetic alterations affecting chromosome 11p15.5 cause Beckwith-Wiedemann syndrome (BWS,OMIM#130650), which is a congenital overgrowth disorder with an incidence of about one in 13,000. BWS has a complex phenotype typically including prenatal and postnatal overgrowth, macrosomia, exomphalos, umbilical hernia, hemihypertrophy, and hypoglycaemia in the neonatal period. Affected patients also have increased risk for developing tumors in childhood, including Wilms' tumor, adrenal cortical carcinomas, and hepatoblastoma [2]. However, the frequency of tumor occurrence in BWS patients have varied from studies. Molecular genetic diagnosis would facilitate the subtyping of BWS and identifies individuals who require the surveillance due to increased risk of pediatric tumors.

The molecular etiology of BWS is complex and several subtypes have been described. Up to 80% of sporadic cases are due to epigenetic-genetic alterations and about 15–20% BWS patients do not have a known genetic defect. About 85% of BWS cases occur sporadically and 15% have familial transmission. Among BWS patients with a defined genetic defect, 50% are caused by hypomethylation...
of IC2 leading to loss of methylation at the KCNQ1OT1:TSS DMR (differentially methylated region), 5–10% by hypermethylation of H19/IGF2:IG DMR resulting in bi-allelic expression of the IGF2 (insulin like growth factor 2) gene and absence of H19 gene expression, 20% by aberrant methylation patterns on both imprinted gene clusters due to segmental paternal uniparental disomy (UPD) covering 11p15, 8% by germline CDKN1C mutations, and about 1–2% by a paternal duplication or a balanced rearrangement of chromosome 11p15 [2–5]. Most of the duplication cases result from unbalanced segregation of a paternal translocation or inversion. However, paternal derived de novo duplications involving 11p15.5 have also been described [2, 3]. The identified duplication is predicted to affect the dosage and expression of paternally expressed genes including overexpression of IGF2 gene, as well as non-imprinted genes. An integrated molecular approach is required to provide accurate diagnosis of BWS. Proper subtyping of epigenetic-genetic alterations in BWS patients could lead to better understanding of disease course, effective treatment of symptoms, and preventive management of tumor risk.

Case presentation
Two patients were referred for genetic evaluation at the prenatal diagnosis and genetic counseling clinic in Shenzhen Maternal and Child Healthcare Hospital. This study was approved by the hospital’s Institutional Review Board and written informed consents for publication of their clinical details and/or clinical images were obtained from the patient or parents.

Patient 1 was a 27-year-old G1P0 woman with no significant past medical, surgical or family history. Fetal ultrasound screening in the 24 weeks of gestation was unremarkable except for mild enlargement of renal. By week 30, ultrasonography examination identified a protruding tongue and enlargement kidney and liver. The follow-up ultrasound study by week 34 confirmed macroglossia, nephromegaly and hepatomegaly in the fetus (Fig. 1a–c). Polyhydramnios (AFI = 22.26 cm, 75th -95th percentile), increased abdominal circumference (AC = 34.34 cm, 75th -95th percentile) and an increased estimated fetal weight (EFW = 3228 g, >95th percentile) were also noted.

Patient 2 was a 2-month-old baby girl with weight 4.35 kg (15th percentile) and length 53.5 cm (under 15th percentile). She came from a rural country of Guangdong province. Her mother did not have prenatal tests during the pregnancy, no miscarriages history and the family had no medical history of BWS. After birth, she showed macroglossia, earlobe crease, hypermyotonia and had feeding and airway issues. The macroglossia was evident at 2 months of age (Fig. 2a). Patient 2 was able to eat and speak normally and has reduced macroglossia at 32 months old (Fig. 2b). Physical examination at local hospital by physician showed normal development (weight 13.2 kg, 50th percentile), height 91 cm, <50th percentile) and no abnormal ultrasound examination results were found.
In patient 1, chromosome analysis showed a normal male karyotype (46,XY). Chromosome microarray analysis (CMA) was performed for patient 1 using the Affymetrix Cytoscan 750 K array (Affymetrix, Santa Clara, CA, USA) by following the manufacturer’s instructions. The CMA result revealed an 896 k-base (Kb) duplication at 11p15.5 (arr[GRCh37]11p15.5(1,632,167–2,527,910)×3) including genes from CTSD to TRPM5 (Fig. 1d). The MS-MLPA (Amsterdam, The Netherlands; SALSA MLPA kit ME030-B2) result showed copy number changes with an increased mean peak height ratio of 1.5. This was interpreted as a trisomic pattern for the 11p15 IC1 region and exclude the duplication of the IC2 region (Fig. 1e). The methylation status was gain of methylation at IC1 with a methylation index of 0.76 and normal methylation status on IC2 with a methylation index of 0.61 in comparison with normal control methylation index of 0.65 at IC1 and methylation index of 0.62 at IC2 (Fig. 1f). Six normal cord blood control samples were analyzed for patient 1. Normal methylation ranges at IC1 and IC2 were calculated from the control samples. The IC1 and IC2 methylation indices were referred to the established ranges [6]. After comprehensive counseling of the genetic test results and associated disease phenotypes, the couple made an informed decision to terminate the pregnancy. Follow-up chromosome analysis, CMA and MS-MLPA performed for the couple found normal results.

In patient 2, chromosome analysis showed a normal female karyotype (46,XX). Array comparative genomic hybridization analysis was performed for patient 2 using the SurePrint G3 Human CGH 8x60K Microarray Kit (Agilent Technologies, Santa Clara, CA, USA) by following a previous described procedure [7]. The aCGH result showed a 228.8Kb deletion at 11p15.5 including genes from SIRT3 to ANO9 and a 2.5 Mb duplication at 11p15.5–15.4 (arr[GRCh36]11p15.5(208,165–436,954)×1,11p15.5p15.4(497,819–2,996,618)×3) (Fig. 2c). The MS-MLPA (Amsterdam, The Netherlands; SALSA MLPA kit ME030-B2) result showed copy number changes with an increased mean peak height ratio of 1.5. This was interpreted as a trisomic pattern for this chromosomal region (Fig. 2d). The methylation status was gain of methylation at IC1 with methylation index of 0.75 and normal methylation status at IC2 with methylation index of 0.42 in comparison with normal control methylation index of 0.58 at IC1 and 0.56 at IC2 (Fig. 2e). Ten normal peripheral blood control samples were analyzed for patient 2. Follow-up parental chromosome analysis, CMA and MS-MLPA found normal results.

**Discussion**

In this study we report two Chinese BWS cases with de novo paternally derived duplication at 11p15.5. For patient 1, the findings of macroglossia, nephromegaly and hepatomegaly by ultrasound examinations and the results from CMA and MS-MLPA analysis fulfilled the diagnostic criteria for BWS with low tumor risk. Currently, there have been more than 150 BWS cases diagnosed prenatally [8–15]. With the growing knowledge about BWS and the currently applied molecular tests techniques in BWS, the number of positively tested BWS patients has increased including prenatal patients [8]. However, challenges exist for prenatal diagnosis of BWS. Mosaicism is a major challenge. In case of low-rate mosaicism, the...
negative result will be generated and the suspected cases will escape the detection. Since there is variable degree of methylation in different tissues of imprinting disease patients, to test another tissue (fibroblasts, buccal cells) in prenatal diagnosis of BWS is not easy to achieve. Another challenge is that the diagnostic work-up in BWS needs multi-method approaches and knowledge of limitations of the applied because of the clinical heterogeneity and the molecular complexity of the disorder [16].

In patient 2, aCGH test revealed a 2.5 Mb duplication at 11p15.5–15.4 and a 228.8Kb microdeletion at 11p15.5. This terminal deletion includes the SIRT3, PSMD13, NLRP6, ATHL1, IFITM1, IFITM3, B4GALNT4, PKP3, SIGIRR, and ANO9 genes. The NAD-dependent deacetylase sirtuin-3 (SIRT3) gene, a member of the sirtuin family of protein, is an important regulator of cell metabolism. SIRT3 plays a key role in cellular respiration, metabolism, aging-related disease and cancer [17]. The NLRP6 gene, a member of the nucleotide-binding oligomerization domain-like receptor (NLR) family member, has been implicated in inflammasome signaling to activate caspase-1. NLRP6 plays critical role for protection against inflammation-related colon tumorigenesis [18]. Patient 2 had the de novo duplication at 11p15 and can be classified into low tumor risk [19]. Interestingly, the clinical feature of macroglossia resolves spontaneously. It has been observed that some features mitigate during the growth of BWS patient as reported in previous studies [3, 11, 20]. For patient 2, physical examination should be performed routinely for potential intellectual disability and the possible clinical effect involving the deleted genes.

Review of literature found six reports with known size of paternally derived duplications involving in BWS [6, 9, 14, 21–23]. The duplication segments ranged in size from 0.3 Mb to 25 Mb (Fig. 3). The breakpoints position of duplication segment less than 2.0 Mb differ while invariably fall within the IC1 or IC2 region, which suggests that the genomic instability in this region may directly related to the genomic structure. The non-recurrent genomic replication is probably mediated by the non-allelic homologous recombination (NAHR) which results in the overexpression of IGF2. The previous studies have revealed that recurrent CNVs are characterized by higher GC content and hot spot motif [24]. The methylation aberration of KCNQ1OT1:TSS DMR or H19/IGF2:IG DMR, and the breakpoints sequence analysis should be further studied in this highly genomic instability region. The identification of more cases with duplication at 11p15.5 imprinted domain may bring new insights into the regulation mechanism of genomic imprinting at both IC1 and IC2 [9]. Furthermore, chromosome duplications or deletions have been infrequently reported in North American and European patients. It is estimated that about 1–2% of the BWS patients have a chromosome duplication or a rearrangement (inversion or translocation) [5]. A recent study of 47 Japanese BWS patients revealed a significantly higher frequency of chromosome abnormality (13%) and extremely low frequency of H19/IGF2:IG DMR hypermethylation (0%). The data suggested that susceptibility to epigenetic and genetic alterations leading to BWS varied according to ethnicity [25]. A recent study in a serial of over 400 BWS cases also indicated that copy number changes in the 11p15.5 region contributed significantly to the etiology of the BWS [6]. Large case series to systematically evaluate the subtype frequency of BWS in Chinese population is essential to find out the underlying

![Fig. 3 Six reports with known size of paternally derived duplications involving in BWS. Duplication segments were depicted in solid line and the dash line represents the exceeding length. The citation number is noted on the right. Drawing is not to scale.](image-url)
environmental or genetic factors. The existence of low copy repeats and segmental duplications as hot-spot for copy number changes at 11p15.5 should be investigated further, especially in East Asian population [21, 26].

Conclusion
In conclusion, we first reported two Chinese BWS patients caused by paternal derived de novo duplication at 11p15. More cases should be collected to study whether there is ethnicity genetic background difference for various subtypes of epigenetic-genetic alterations. Identifying the underlying genetic mechanisms causing BWS is important for informative genetic counseling, effective disease treatment, recurrence and tumor risk management.

Acknowledgements
The authors appreciate the families to take part in this study and permission for publication of their clinical details and/or consent for publication. The authors declare that they have no competing interests.

Funding
This work was supported by Shenzhen Science and Technology Innovation Committee (Grant Number JCYJ20170413092818116), National Natural Science Foundation of China (Grant Number 81601299).

Availability of data and materials
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Authors’ contributions
WQ, performed MS-MLPA, data analysis, literature review and drafted the manuscript; QZ, performed CMA and aCGH analysis; FL, performed chromosome analysis; PL, reviewed results and revised the manuscript; XJ, WQ, performed MS-MLPA, data analysis, literature review and drafted the manuscript. All authors read and approved the final manuscript.

Ethics approval and consent to participate
A statement on ethics approval and consent for this study was approved by Ethics approval and consent to participate in the Healthcare Hospital. Written informed consents for publication of their clinical details and/or consent for publication in this study were obtained from the patient or parents.

Consent for publication
Written informed consents for publication of their clinical details and/or clinical images were obtained from the patient or parents.

Competing interests
The authors declare that they have no competing interests.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Author details
1 Shenzhen Maternity and Child Healthcare Hospital, 3012 Fuqiang Road, Shenzhen, Guangdong 518028, China. 2 First Affiliated Hospital, Biomedical Translational Research Institute, Jinan University, Guangzhou, Guangdong, China. 3 Department of Genetics, Yale School of Medicine, New Haven, CT, USA.

Received: 28 November 2017 Accepted: 11 December 2017
Published online: 19 December 2017

References
1. Reik W, Walter J. Genomic imprinting: parental influence on the genome. Nat Rev Genet. 2001;2(1):21–32.
2. Choufani S, Shuman C, Weksberg R. Beckwith-Wiedemann syndrome. Am J Med Genet C Semin Med Genet. 2010;154C(3):343–54.
3. Weksberg R, Shuman C, Beckwith JB. Beckwith-Wiedemann syndrome. Eur J Hum Genet. 2010;18(1):8–14.
4. Eggermann T, Algar E, Lapunzina P, Mackay D, Maher E, Mannens M, Netchine I, Prawitt D, Riccio A, Temple IK, Weksberg R. Clinical utility gene card for: Beckwith-Wiedemann syndrome. Eur J Hum Genet. 2014;22(3).
5. Cooper WN, Luharia A, Evans GA, Raza H, Haire AC, Grundy R, Bowdin SC, Riccio A, Sebastio G, Bliik J, Schofield PN, Reik W, Macdonald F, Maher E. Molecular subtypes and phenotypic expression of Beckwith-Wiedemann syndrome. Eur J Hum Genet. 2005;13(9):1025–32.
6. Baskin B, Choufani S, Chen YA, Shuman C, Parkinson N, Lemyre E, Micheil Innes A, Stavrakopulos DJ, Ray PN, Weksberg R. High frequency of copy number variations (CNVs) in the chromosome 11p15 region in patients with Beckwith-Wiedemann syndrome. Hum Genet. 2014;133(3):321–30.
7. Wang Q, Wu W, Xu Z, Luo F, Zhou Q, Li P, Xie J. Copy number changes and methylation patterns in an isodicentric and a ring chromosome of 15q11-q13: report of two cases and review of literature. Mol Cytogenet. 2015;8:97.
8. Williams DH, Gauthier DW, Mailing M. Prenatal diagnosis of Beckwith-Wiedemann syndrome. Prenat Diagn. 2005;25(10):879–84.
9. Demars J, Rossignol S, Netchine I, Lee KS, Shmela M, Faivre L, Weill J, Odent S, Azzi A, Callier P, Lucas J, Dubourg C, Andreius L, Le Bocu Y, El-Osta A, Gicquel C. New insights into the pathogenesis of Beckwith-Wiedemann and silver-Russell syndromes: contribution of small copy number variations to 11p15 imprinting defects. Hum Mutat. 2011;32(10):1711–22.
10. Calveillo M, Tabano S, Colapietro P, Maizt S, Pansa A, Aucello C, Lalatta F, Gentilini B, Spreafico F, Calzari L, Perotti D, Larizza L, Russo S, Selcomini A, Sirchia SM, Miozzo M. Quantitative DNA methylation analysis improves epigenotype-phenotype correlations in Beckwith-Wiedemann syndrome. Epigenetics. 2013;8(10):1053–60.
11. Niederhofer KT, Penaherrera M, Pugash D, Rupps R, Harbour L, Tesfier Y, Choufani S, Zhao C, Manichinho I, Shuman C, Robinson WP, Weksberg R. Boerkoel CF. Beckwith-Wiedemann syndrome in sibs discordant for IC2 methylation. Am J Med Genet A. 2012;158A(7):1662–9.
12. Paganini L, Carlessi N, Fontana L, Silipigni R, Motta S, Fioni S, Guerrieri S, Lalatta C, Fera C, Sirchia S, Miozzo M, Tabano S. Beckwith-Wiedemann syndrome prenatal diagnosis by methylation analysis in chorionic villi. Epigenetics. 2015;10(7):643–9.
13. Eggermann T, Brioude F, Russo S, Lombardi MP, Bliik J, Maher ER, Larizza L, Prawitt D, Netchine I, Gonzales M, Grinskis K, Turner Z, Monck D, Mannens M, Chrzanovska W, Wisse RG, Beemers M, Stassen RW, Eggemann K, Tenorio J, Neve JD, Moore GE, Mackay DJ, Temple K, Gillessen-Kaesbach G, Ogata T, Weksberg R, Algar E, Lapunzina P. Prenatal molecular testing for Beckwith-Wiedemann syndrome: a challenge for molecular analysis and counseling. Prenat Diagn. 2005;25(10):879–93.
14. Chen KJ, Liu YM, Li CH, Chang YL, Chang SD. Prenatal diagnosis of paternal duplication of 11p15.5–>14.3: its implication of Beckwith-Wiedemann syndrome. Taiwan J Obstet Gynecol. 2016;55(6):877–80.
15. Reise O, Lerer J, Amlie A, Heyman E, Herrman A, Dolfin T, Abelowich D. Wiedemann-Beckwith syndrome: further prenatal characterization of the condition. Am J Med Genet. 2002;107(3):209–13.
16. Russo S, Calzari L, Musa A, Mainini E, Canzio M, Di Candia S, Clementi M, Guzzetti L, Tabano S, Missozzi M, Sirchia S, Finelli P, Piontera P, Maizt S, Sorge G, Calcagno A, Manfredini E, Ferrero GB, Pecile V, Larizza L. A multi-method approach to the molecular diagnosis of overt and borderline 11p15.5 defects underlying silver-Russell and Beckwith-Wiedemann syndromes. Clin Epigenetics. 2016;8:23.
17. Yu FY, Xu Q, Wu DD, Lai AT, Xu Y. The prognostic and Clinicalpathological roles of Survivin-3 in various cancers. PLoS One. 2016; 11(8):e0159801.
18. Anand PK, Malireddi RK, Lukens JR, Vogel P, Berton J, Lamkanfi M, Kanneganti TD. NLPR6 negatively regulates innate immunity and host defence against bacterial pathogens. Nature. 2012;488(7411):389–93.
19. Rump P, Zeeegers MP, van Essen AJ. Tumor risk in Beckwith-Wiedemann syndrome: a review and meta-analysis. Am J Med Genet A. 2005;136(1):95–104.
20. Val A, Kehre T, Mee P, Muru K, Kallaks E, Zilina O, Tillmann V, Junap K, Familial 1.3-Mb 11p15.5p15.4 duplication in three generations causing silver-Russell and Beckwith-Wiedemann syndromes. Mol Syndromol. 2015; 6(3):147–51.
21. Russo S, Finelli P, Recalcati MP, Ferriauolo S, Cloganti F, Dalla Bernardina B, Tibiletti MG, Agosti M, Sala M, Bonati MT, Larizza L. Molecular and genomic
characterisation of cryptic chromosomal alterations leading to paternal duplication of the 11p15.5 Beckwith-Wiedemann region. J Med Genet. 2006;43(8):e39.

22. Bliek J, Snijder S, Maas SM, Polstra A, van der Lip K, Alders M, Kneet AC, Mannens MM. Phenotypic discordance upon paternal or maternal transmission of duplications of the 11p15 imprinted regions. Eur J Med Genet. 2009;52(6):404–8.

23. Cardarelli L, Sparago A, De Crescenzo A, Nalesso E, Zavan B, Cubellis MV, Selicomi A, Cavicchioli P, Pozzan GB, Petrella M, Riccio A. Silver-Russell syndrome and Beckwith-Wiedemann syndrome phenotypes associated with 11p duplication in a single family. Pediatr Dev Pathol. 2010;13(4):326–30.

24. Dittwald P, Gambin T, Szafranski P, Li J, Arnato S, Divon MY, Rodriguez Rojas LX, Elton LE, Schaff CP, Torres-Martinez W, Stevens AK, Rosenfeld JA, Agadi S, Francis D, Kang SH, Breman A, Lalani SR, Bacino CA, Bi W, Milosavljevic A, Beaudet AL, Patel A, Shaw CA, Lupski JR, Gambin A, Cheung SW, Stankiewicz P. NAHR-mediated copy-number variants in a clinical population: mechanistic insights into both genomic disorders and Mendelian traits. Genome Res. 2013;23(9):1395–409.

25. Sasaki K, Soejima H, Higashimoto K, Yatsuki H, Ohashi H, Yakabe S, Joh K, Nikiwa N, Mukai T. Japanese and north American/European patients with Beckwith-Wiedemann syndrome have different frequencies of some epigenetic and genetic alterations. Eur J Hum Genet. 2007;15(12):1205–10.

26. Soejima H, Higashimoto K. Epigenetic and genetic alterations of the imprinting disorder Beckwith-Wiedemann syndrome and related disorders. J Hum Genet. 2013;58(7):402–9.